Obesity drugmaker Novo Nordisk downgraded its 2025 sales forecast on Wednesday, ending a four-year stretch of steady guidance ...

Not long ago the largest company by market capitalization in Europe, the evolution of the weight loss medicine market has ...

Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.

CVS Health Corp.’s drug-benefits unit negotiated a deal to make Novo Nordisk A/S’s Wegovy more widely available to its ...

This marks a shift in the agency's approach to treating the global obesity problem. Read more at straitstimes.com. Read more ...

Prior to starting the trial, the participants also had moderate to high levels of scar tissue in the liver, known as stage 2 ...

The deal could expand access to its in-demand obesity drug at the expense of Eli Lilly, whose shares fell by double digits on ...

As summer approaches, millions of Americans are turning to weight-loss injections in hopes of shedding pounds—fast. Roughly ...

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

Novo Nordisk A/S said it would sell its popular weight-loss drug Wegovy for a steeply reduced price on several telehealth ...

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.